Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy

Table 2

Actionable targets identified by molecular profiling in the study cohort.

Target	Number of patients out of total evaluable patients ()	Frequency, %
Identified by IHC
Negative/low TS	9/12	75
Negative/low ERCC1	6/12	50
High TOPO1	6/13	46
High SPARC	4/11	36
Low MGMT	3/14	21
High TOP2A	2/11	18
Positive AR	2/14	14
Positive ER/PgR	2/14	14
Positive HER2	0/14	0
Identified by microarray analysis
KIT overexpression	4/6	67
TOP2B overexpression	4/6	67
PDGFRA overexpression	3/6	50
PDGFRB overexpression	3/6	50
TOP2A overexpression	3/6	50
TYMS overexpression	2/6	33
VDR overexpression	2/6	33
ESR1 overexpression	2/6	33
SPARC overexpression	2/6	33
MGMT underexpression	2/6	33

SPARC was considered high if either of the SPARC assays (using monoclonal or polyclonal anti-SPARC antibodies) was positive.
AR: androgen receptor; ER: estrogen receptor; ERCC1: excision repair cross-complementation 1; ESR1: estrogen receptor 1; HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry; MGMT: O-6-methylguanine-DNA methyltransferase; PDGFRA/B: platelet-derived growth factor receptor alpha/beta; PgR: progesterone receptor; SPARC: secreted protein acidic and rich in cysteine; TOPO1: topoisomerase I; TOP2A/B: topoisomerase IIA/B; TS/TYMS: thymidylate synthase; VDR: vitamin D receptor.